Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1(2,3,4,5- tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1261-1269

  Hirai, Keisuke ^a   Kato, Koki ^a   Nakayama, Takahiro ^a   Hayako, Hitomi ^a   Ishihara, Yuji ^a   Goto, Giichi ^a   Miyamoto, Masaomi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DESIPRAMINE; DOPAMINE; IMIPRAMINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; PHYSOSTIGMINE; PIRENZEPINE; PROFENAMINE; SEROTONIN; SPIPERONE; TACRINE; ZANEPEZIL;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; DOPAMINE BLOOD LEVEL; ENZYME INHIBITION; LIGAND BINDING; MALE; MONOAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SEROTONIN BLOOD LEVEL; STATISTICAL ANALYSIS;

ACETYLCHOLINESTERASE; ANIMALS; BENZAZEPINES; BIOGENIC MONOAMINES; BUTYRYLCHOLINESTERASE; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; CHOLINESTERASE INHIBITORS; LEARNING; MALE; MEMORY; NOREPINEPHRINE; RATS; RATS, WISTAR; RECEPTORS, CHOLINERGIC; SEROTONIN; TACRINE;

EID: 0030973899     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. AIGNER, T., MITCHELL, S. J., AGGLETON, J. P., DELONG, M. R., STRUBLE, R. G., PRICE, D. L., WENK, G. L. AND MISHKIN, M.: Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92: 292-300, 1987.
2. BARTUS, R. T., DEAN, R. L., BEER, B. AND LIPPA, A. S.: The cholinergic hypothesis of geriatric memory dysfunction. Science (Wash. DC) 217: 408-417, 1982.
3. 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in striatum. Life Sci. 35: 1885-1893, 1984.
4. BONDAREFF, W., MOUNTJOY, C. Q. AND ROTH, M.: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurobiology 32: 164-168, 1982.
5. 3H]N-methyl-carbamylcholine, a new radioligand specific for nicotinic acetylcholine receptor in brain. Eur. J. Pharmacol. 139: 232-333, 1987.
6. BRIMIJOIN, S.: Molecular forms of acetylcholinesterase in brain, nerve and muscle: Nature, localization and dynamics. Prog. Neurobiol. 21: 291-322, 1983.
7. 1 muscarinic agonist Xanomeline (LY246708/NNC11-0232). J. Pharmacol. Exp. Ther. 269: 282-289, 1994.
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
9. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cholinergic innervation. Science (Wash. DC) 219: 1184-1190, 1983.
10. 3H-Spiroperidol labels dopamine receptors in pituitary and brain. Eur. J. Pharmacol. 46: 377-381, 1977.
11. CURCIO, C. A. AND KEMPER, T.: Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J. Neuropathol. Exp. Neurol. 43: 359-368, 1984.
12. DAVIES, P., KATZMAN, R. AND TERRY, R. D.: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288: 279-280, 1980.
13. DAVIS, P. AND MALONEY, A. J. F.: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1997.
14. DAVIS, K. L., THAL, L. J., GAMZU, E. R., DAVIS, C. S., WOOLSON, R. F., GRACON, S. I., DRACHMAN, D. A., SCHNEIDER, L. S., WHITEHOUSE, P. J., HOOVER, T. M., MORRIS, J. C., KAWAS, C. H., KNOPMAN, D. S., EARL, N. L., KUMAR, V., DOODY, R. S. AND THE TACRINE COLLABORATIVE STUDY GROUP: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327: 1253-1259, 1992.
15. DRACHMAN, D. A.: Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27: 783-790, 1977.
16. DRACHMAN, D. A. AND LEAVITT, J.: Human memory and the cholinergic system. Arch. Neurol. 30: 113-121, 1974.
17. DRESSEL, T. D., GOODALE, R. L., BORNER, J. W. AND ETANI, S. E.: A study of the cholinesterase of the canine pancreatic sphincters and the relationship between reduced butyrylcholinesterase activity and pancreatic ductal hypertension. Ann. Surg. 192: 614-618, 1980.
18. DRUKARCH, B., LEYSEN, J. E. AND STOOF, J. C.: Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci. 42: 1011-1017, 1988.
19. ELLMAN, G. L., COURTNEY, K. D., ANDRES, V. AND FEATHERSTONE, R. M.: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88-95, 1961.
20. FLYNN, D. D. AND MASH, D. C.: Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J. Pharmacol. Exp. Ther. 250: 573-581, 1989.
21. FONNUM, F.: A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24: 407-409, 1975.
22. GOTTFRIES, C. G.: Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology 86: 245, 1985.
23. 3HDPAT. Nature 305: 140-142, 1983.
24. GRENHOFF, J. AND SVENSSON, T. H.: Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine. Naunyn-Schmiedeberg Arch. Pharmacol. 346: 395-398, 1992.
25. GRUBER, R. P., STONE, G. C. AND REED, D. K.: Scopolamine-induced anterograde amnesia. Neuropharmacology 6: 186-190, 1967.
26. GUPTA, R. C. AND DETTBARN, W. D.: iso-OMPA-induced potentiation of soman toxicity in rat. Arch. Toxicol. 61: 58-62, 1987.
27. HALLIWELL, J. V. AND GROVE, E. A.: 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurons. Eur. J. Pharmacol. 163: 369-372, 1989.
28. HARVEY, A. L.: The pharmacology of galanthamine and its analogues. Pharmac. Ther. 68: 113-128, 1995.
29. HELPER, D. J., OLTON, D. S., WENK, G. L. AND COYLE, J. T.: Lesions in nucleus basalis magnocellularis and medial septal area of rats produce qualitatively similar memory impairments. J. Neurosci. 5: 866-873, 1985.
30. HOLFORD, N. H. G. AND REACE, K. E.: Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. U.S.A. 89: 11471-11475, 1992.
31. ISHIHARA, Y., HIRAI, K., MIYAMOTO, M. AND GOTO, G.: Central cholinergic agents. 6. Synthesis and evaluation of 3[1-(phenylmethyl)-4-piperidinylJ-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1- propanones and their analogs as central selective acetylcholinesterase inhibitors. J. Med. Chem. 37: 2292-2299, 1994.
32. JBILO, O., BARTELS, C. F., CHATONNET, A., TOUTANTI, J.-P. AND LOCKRIDGE, O.: Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32: 1445-1457, 1994.
33. JOHNSON, C. D. AND RUSSELL, R. L.: A rapid simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal. Biochem. 64: 229-238, 1975.
34. JOSSAN, S. S., ADEM, A., WINBLAD, B. AND ORELAND, L.: Characterization of dopamine and serotonin uptake inhibitory effects of tetrahydroaminoacridine in rat brain. Pharmacol. Toxicol. 71: 213-215, 1992.
35. KATZMAN, R.: Alzheimer's disease. N. Engl. J. Med. 315: 964-973, 1986.
36. KLEINBERGER, N. AND YANAI, J.: Early phenobarbital-induced alterations in hippocampal acetylcholinesterase activity and behavior. Dev. Brain Res. 22: 113-123, 1985.
37. KNAPP, M. J., KNOPMAN, D. S., SOLOMON, P. R., PENDLEBURG, W. W., DAVIS, C. S. AND GRACON, S. I.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271: 985-991, 1994.
38. KOBAYASHI, R. M., PALKOVITS, M., HRUSKA, R. E., ROTHSCHILD, R. AND YAMAMURA, H. I.: Regional distribution of muscarinic cholinergic receptors in rat brain. Brain Res. 154: 13-23, 1978.
39. KOELLE, W. A., KOELLE, G. B. AND SMYRL, E. G.: Effects of persistent selective suppression of ganglionic butyrylcholinesterase on steady state and regenerating levels of acetylcholinesterase: Implications regarding function of butyrylcholinesterase and regulation of protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 73: 2936-2938, 1976.
40. 3H-ligand for serotonin2 receptor binding sites. Mol. Pharmacol. 21: 301-314, 1982.
41. LOEWENSTEIN-LIGHTENSTEIN, Y., SCHWARZ, M., GLICK, D., NORGAARD-PEDERSEN, B., ZAKUT, H. AND SOREQ, H.: Genetic predisposition to adverse consequences of anti-cholinesterases in "atypical' BCHE carriers. Natl. Med. 1: 1082-1085, 1995.
42. MANN, D. M. A., YATES, P. O. AND MARCYNIUK, B.: A comparison of change in the nucleus basalis and locus coerleus in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 47: 201-203, 1984.
43. MARCYNIUK, B., MANN. D. M. AND YATES, P. O.: The topography of cell loss from locus coeruleus in Alzheimer's disease. J. Neurol. Sci. 76: 335-345, 1986.
44. 3H]AF-DX 384 to cloned and native muscarinic receptors. J. Pharmacol. Exp. Ther. 259: 601-607, 1991.
45. MIYAMOTO, M., KATO, J., NARUMI, S. AND NAGAOKA, A.: Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. Brain Res. 419: 19-31, 1987.
46. MIYAMOTO, M., NARUMI, S., NAGAOKA, A. AND COYLE, J. T.: Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J. Pharmacol. Exp. Ther. 248: 825-835, 1989.
47. MIYAMOTO, M., SHINTANI, M., NAGAOKA, A. AND NAGAWA, Y.: Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks. Brain Res. 328: 97-104, 1985.
48. MIYAMOTO, M., TAKAHASHI, H., KATO, K., HIRAI, K., ISHIHARA, Y. AND GOTO, G.: Effects of 3-[1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. J. Pharmacol. Exp. Ther. 277: 1292-1304, 1996.
49. 3H]prazosin binding. Mol. Pharmacol. 29: 321-330, 1986.
50. NILSSON, L., ADEM, A., HARDY, J., WINBLAD, B. AND NORDBERG, A.: Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J. Neural Transm. 70: 357-368, 1987.
51. 3H]Rauwolscine (α-yohimbine): A specific antagonist radioligand for brain α 2-adrenergic receptors. Eur. J. Pharmacol. 76: 461-464, 1981.
52. PERRY, E. K., CURTIS, M., PICK, D. J., CANDY, J. M., ATACK, J. R., BLOXHAM, C. A., BLESSED, G., FAIRBAIRN, A. W., TOMLINSON, B. E. AND PERRY, R. H.: Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparison with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 48: 413-421, 1985.
53. PERRY, E. K., GIBSON, P. H., BLESSED, G., PERRY, R. H. AND TOMLINSON, B. E.: Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase in necropsy brain tissue. J. Neurol. Sci. 34: 247-265, 1977.
54. PRODY, C. A., DREYFUS, P., ZAMIR, R., ZAKUT, H. AND SOREQ, H.: De nova amplification within a "silent' human cholinesterase gene in a family subjected to prolonged exposure to organophosphorus insecticides. Proc. Natl. Acad. Sci. U.S.A. 86: 690-694, 1989.
55. ROSSOR, M. N. AND EMSON, P. C.: Neuropeptides in degenerative diseases of the central nervous system. Trends Neurosci. 5: 399-401, 1982.
56. SEGAL, M., DUDAI, Y. AND AMSTERDAM, A.: Distribution of an alpha-bungarotoxin-binding cholinergic nicotinic receptor in rat brain. Brain Res. 148: 105-119, 1978.
57. SELKOE, D. J.: Normal and abnormal biology of the beta-amyloid precursor protein. Ann. Rev. Neurosci. 17: 489-517, 1994.
58. SIMON, J. R., ATWEH, S. AND KUHER, M. J.: Sodium-dependent high-affinity choline uptake: A regulatory step in the synthesis of acetylcholine. J. Neurochem. 26: 909-922, 1976.
59. SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., PROVENZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. AND KLENK, D. C.: Measurement of protein using bicinchonic acid. Anal. Biochem. 193: 76-85, 1985.
60. SOREQ, H. AND ZAKUT, H.: Human Cholinesterases and Anticholinesterases, ed. by R. S. Sparkes, Karger, Basel, Switzerland, 1990.
61. SUGIMOTO, H., IIMURA, Y., YAMANISHI, Y. AND YAMATSU, K.: Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38: 4821-4829, 1995.
62. SUMMERS, W. K., MAJOVSKI, L. V., MARSH, G. M., TACHIKI, K. AND KLING, A.: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315: 1241-1245, 1986.
63. 3H]Pirenzepine selectively identifies a high-affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. Life Sci. 31: 1237-1239, 1982.
64. WHITEHOUSE, P. J., PRICE, D. L., STRUBLE, R. G., CLERK, A. W., COYLK, J. T. AND BELONG, M. R.: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (Wash. DC) 215: 1237-1239, 1982.
65. YAMAMOTO, T. AND HIRANO, A.: Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons. Ann. Neurol. 17: 573-577. 1985.